Epilepsies, Partial

6
Pipeline Programs
2
Companies
7
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
2
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
GABAPENTINApproved
gabapentin
Unknown Company
oral2010
Pfizer
NEURONTINApproved
gabapentin
Pfizer
oral2002

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
1
gabapentinPhase 31 trial
Active Trials
NCT00603473Completed92Est. Dec 2009
UP
UCB PharmaBelgium - Brussels
6 programs
2
1
Levetiracetam 250 mgPhase 31 trial
SPM 927Phase 2/31 trial
SeletracetamPhase 2/31 trial
LacosamideN/A1 trial
LacosamideN/A1 trial
+1 more programs
Active Trials
NCT00771927Completed1,005Est. Mar 2012
NCT03559673No Longer Available
NCT01098162Completed576Est. Jul 2013
+3 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizergabapentin
UCB PharmaLevetiracetam 250 mg
UCB PharmaSeletracetam
UCB PharmaSPM 927
UCB PharmaVimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
UCB PharmaLacosamide

Clinical Trials (7)

Total enrollment: 2,185 patients across 7 trials

A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures

Start: Jan 2008Est. completion: Dec 200992 patients
Phase 3Completed
NCT00280696UCB PharmaLevetiracetam 250 mg

A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures

Start: Nov 2005Est. completion: Nov 2007352 patients
Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures

Start: May 20080
Phase 2/3Withdrawn

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

Start: Feb 2005Est. completion: May 2006160 patients
Phase 2/3Completed

Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures

N/ANo Longer Available
NCT01098162UCB PharmaVimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug

Start: Mar 2010Est. completion: Jul 2013576 patients
N/ACompleted

Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures

Start: Oct 2008Est. completion: Mar 20121,005 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space